Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Authors
Keywords
NK cells, T cells, Human cytomegalovirus, Viral replication, Cytotoxic T cells, Human metapneumovirus infection, Chronic kidney disease, Multiple myeloma
Journal
PLoS One
Volume 14, Issue 2, Pages e0211927
Publisher
Public Library of Science (PLoS)
Online
2019-02-14
DOI
10.1371/journal.pone.0211927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced NK cell IFN-γ secretion and psychological stress are independently associated with herpes zoster
- (2018) Choon Kwan Kim et al. PLoS One
- Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells
- (2018) Hong-Sheng Dai et al. Frontiers in Immunology
- Herpes virus seroepidemiology in the adult Swedish population
- (2017) Jan Olsson et al. Immunity & Ageing
- Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
- (2016) T. Plesner et al. BLOOD
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans
- (2016) A. B. Bigley et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis
- (2016) Benjamin W. Teh et al. EUROPEAN JOURNAL OF CANCER
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
- (2016) Wei Hseun Yeap et al. Scientific Reports
- Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
- (2015) Evren Alici et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cytomegalovirus reactivation in patients with multiple myeloma
- (2015) Tetsuo Hasegawa et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network
- (2013) F. Marchesi et al. Transplant Infectious Disease
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Seropositivity to Cytomegalovirus, Inflammation, All-Cause and Cardiovascular Disease-Related Mortality in the United States
- (2011) Amanda M. Simanek et al. PLoS One
- Characterization of Natural Killer Cell Phenotype and Function during Recurrent Human HSV-2 Infection
- (2011) Niklas K. Björkström et al. PLoS One
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Innate and Adaptive Immune Responses to Herpes Simplex Virus
- (2009) Tracy Chew et al. Viruses-Basel
- CMV infections after hematopoietic stem cell transplantation
- (2008) P Ljungman BONE MARROW TRANSPLANTATION
- Natural Killer Cells as Novel Helpers in Anti-Herpes Simplex Virus Immune Response
- (2008) S. Nandakumar et al. JOURNAL OF VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started